01 1Navinta
01 1TAFAMIDIS MEGLUMINE
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-09
Pay. Date : 2024-07-26
DMF Number : 39928
Submission : 2024-07-29
Status : Active
Type : II
20
Navinta Llc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA.
One of their notable products is TAFAMIDIS MEGLUMINE, with a corresponding US DMF Number 39928.
Remarkably, this DMF maintains an Active status since its submission on July 29, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 09, 2024, and payment made on July 26, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II
